You are here: Industry Insights > Influenza

News List

Based on the Current Status of Drug Research and Development Targeting the Pathogenesis of Influenza (Part 2) Xiaomichong
July 12, 2024
Influenza is an acute respiratory infectious disease caused by the influenza virus.
Based on the Current Status of Drug Research and Development Targeting the Pathogenesis of Influenza (Part 1) Xiaomichong
July 12, 2024
Influenza is an acute respiratory infectious disease caused by the influenza virus.
R&D Status of Drugs Based on Influenza Pathogenesis (Part Two) PharmaSources/Xiao Michong
March 16, 2022
Influenza virus RNA polymerase is a protein complex composed of PA, PB1 and PB2 subunits. PA has endonuclease activity and can induce proteolysis. PB1 has RNA polymerase activity...
A Better Anti-Influenza Solution: Roche’s Blockbuster New Drug Applied for Marketing in China PharmaSources/Xiaoyaowan
June 24, 2020
According to the website of the CDE on June 10, the marketing applications of Roche for its new drug Baloxavir Marboxil Tablets in China have been accepted by the CDE.
First people dosed with a quadrivalent seasonal flu mRNA vaccine europeanpharmaceuticalreview
July 09, 2021
The Phase I/II trial will assess the safety, reactogenicity and immunogenicity of Moderna’s mRNA-1010 seasonal flu vaccine.
Sanofi Invests $425M in Flu Vaccine Manufacturing Facility contractpharma
June 18, 2021
Newly licensed U.S. manufacturing facility to increase availability of Fluzone High-Dose Quadrivalent.
First-in-human universal flu vaccine trial begins europeanpharmaceuticalreview
June 03, 2021
The US National Institutes of Health have begun a first-in-human trial to assess the safety and immunogenicity of a potential universal influenza vaccine candidate, FluMos-v1.
Novavax Announces positive preclinical data for combination influenza and COVID-19 vaccine candidate worldpharmanews
May 11, 2021
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced data from a preclinical study of the company's combination quadrivalent seasonal flu vaccine (NanoFlu™) and COVID-19 vaccine candidate.
Cell-based seasonal influenza vaccine safe and effective in children europeanpharmaceuticalreview
May 08, 2021
Phase III data shows Seqirus’ cell-based quadrivalent seasonal influenza vaccine was as effective and safe as an equivalent FDA-approved egg-based vaccine in paediatric patients.
Cidara Therapeutics signs deal with Janssen for antiviral conjugates to prevent, treat influenza expresspharma
April 06, 2021
Cidara Therapeutics announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals to develop and commercialise Cidara’s Cloudbreak antiviral conjugates (AVCs) for the prevention and ...

Previous page 1 2 3 4 5 6 Next page